Neurological Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX. (29th September 2013)

• Record Type: Journal Article
• Authors: Bano, Nusrat; Najam, Rahila; Mateen, Ahmed
• Other Names: Georgoulias Vassilios A. Academic Editor.
• Is Part Of: Chemotherapy research and practice. Volume 2013(2013)
• Publication Date: 2013-09-29
• Subjects: Chemotherapy -- Periodicals; Drug Therapy; Pharmaceutical Preparations; Chemotherapy; Electronic journals; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; 615.58
• DOI: 10.1155/2013/379870
• Languages: English
• ISSNs: 2090-2107

Abstract

Abstract : The study is designed to assess the frequency and severity of few dose limiting neurological adverse effects of four different schedules of FOLFOX. Patients with histologically confirmed advanced colorectal carcinoma (CRC) were included in the study. Toxicity was graded according to CTC v 2.0. The frequency of grade 3 and 4 adverse effects was comparatively assessed in each treatment arm. The difference in the pattern of toxicity between the treatment schedule was evaluated. The most frequent adverse symptom of neurological adverse effect was grade 1 paresthesia in the patients treated with FOLFOX4 schedule. Grade 4 peripheral neuropathy was reported in few patients of FOLFOX7 treatment arm. Frequency and onset of neurological adverse effects like paresthesia, dizziness, and hypoesthesia were significantly different (P < 0.05 ), whereas frequency and onset of peripheral neuropathy were highly significant (P < 0.01 ) in each treatment arm of FOLFOX. Peripheral neuropathy was associated with electrolyte imbalance and diabetes in few patients. Frequency of symptoms, for example, paresthesia, is associated with increased number of recurrent exposure to oxaliplatin (increased number of cycles) even at low doses (85 mg/m 2 ), whereas severity of symptoms, for example, peripheral neuropathy, is associated with higher dose (130 mg/m 2 ) after few treatment cycles.